I'll be happy to be wrong and you may be right.
I've just stopped factoring in any talk of HE, EAMS, or even a partnership with Big Pharma into my calculations.
NWBO is a worthy risk just based upon DCVax L Phase 3 and DCVax Direct.
After the Direct data release and the subsequent price rise, sure, I've been less than thrilled about the stalling of HE but I've accepted it, however grudgingly.
I definitely blame the bureaucrats far more than I blame NWBO for the squandering of the promise of HE to provide early access while its still actually early. This is almost certainly a case of being penny wise and pound foolish here and of refusing to update their old mentality to account for a breathtakingly powerful opportunity.
News 
Market Data 
Discover 
AI
